ADVERSE EVENTS ASSOCIATED WITH ENZYME REPLACEMENT THERAPIES LYSOSOMAL GLYCOGEN-SPECIFIC ENZYME (GAA) MEDICATIONS FOR THE TREATMENT OF POMPE DISEASE

被引：0
|
作者：
Halloush, S. [1 ]
Guo, J. J. [1 ]
机构：
[1] Univ Cincinnati, James L Winkle Coll Pharm, Cincinnati, OH USA
来源：
VALUE IN HEALTH | 2024年 / 27卷 / 06期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
EPH139
引用
收藏
页码：S178 / S179
页数：2
相关论文
共 50 条
  • [31] Combined aerobic exercise and enzyme replacement therapy rejuvenates the mitochondrial-lysosomal axis and alleviates autophagic blockage in Pompe disease
    Nilsson, M. I.
    MacNeil, L. G.
    Kitaoka, Y.
    Suri, R.
    Young, S. P.
    Kaczor, J. J.
    Nates, N. J.
    Ansari, M. U.
    Wong, T.
    Ahktar, M.
    Brandt, L.
    Hettinga, B. P.
    Tarnopolsky, M. A.
    FREE RADICAL BIOLOGY AND MEDICINE, 2015, 87 : 98 - 112
  • [32] 10-year course of treatment with enzyme replacement therapy for childhood-onset Pompe disease
    Ishii, A.
    Mamada, N.
    Tsuji, H.
    Tamaoka, A.
    NEUROMUSCULAR DISORDERS, 2022, 32 : S77 - S77
  • [33] THE LONG-TERM FOLLOW-UP OF ENZYME REPLACEMENT TREATMENT IN LATE ONSET POMPE DISEASE
    Molnar, Maria Judit
    Borsos Beata
    Vardi, Visy Kotalin
    Grosz Zoltan
    Sebok Agnes
    Dezsi Livia
    Almassy Zsuzsanna
    Kerenyi Levente
    Jobbagy Zita
    Javor Laszlo
    Bidlo Judit
    IDEGGYOGYASZATI SZEMLE-CLINICAL NEUROSCIENCE, 2020, 73 (5-6): : 151 - 159
  • [34] Characterization of pre- and post-treatment pathology after enzyme replacement therapy for pompe disease
    Thurberg, Beth L.
    Maloney, Colleen Lynch
    Vaccaro, Charles
    Afonso, Kendra
    Tsai, Anne Chun-Hui
    Bossen, Edward H.
    Kishnani, Priya S.
    O'Callaghan, Michael
    LABORATORY INVESTIGATION, 2006, 86 (12) : 1208 - 1220
  • [35] Optimizing treatment outcomes: immune tolerance induction in Pompe disease patients undergoing enzyme replacement therapy
    Chen, Hui-An
    Hsu, Rai-Hseng
    Fang, Ching-Ya
    Desai, Ankit K.
    Lee, Ni-Chung
    Hwu, Wuh-Liang
    Tsai, Fuu-Jen
    Kishnani, Priya S.
    Chien, Yin-Hsiu
    FRONTIERS IN IMMUNOLOGY, 2024, 15
  • [36] Immunomodulation in Pompe disease: an effective strategy to resume enzyme replacement therapy after life-threatening adverse reactions
    Kern, I
    Caubet, J. C.
    Filaine, P.
    Ruchonnet-Metrailler, I
    Rimensberger, P.
    Corbelli, R.
    SWISS MEDICAL WEEKLY, 2016, 146 : 28S - 28S
  • [37] A NOVEL MUTATION OF THE GAA GENE IN A FINNISH LATE-ONSET POMPE DISEASE PATIENT: CLINICAL PHENOTYPE AND FOLLOW-UP WITH ENZYME REPLACEMENT THERAPY
    Korpela, Mari P.
    Paetau, Anders
    Lofberg, Mervi I.
    Timonen, Marjut H.
    Lamminen, Antti E.
    Kiuru-Enari, Sari M. K.
    MUSCLE & NERVE, 2009, 40 (01) : 143 - 148
  • [38] Early signs of benefit in a child with late-onset Pompe disease after treatment with enzyme replacement therapy
    Lianou, D.
    Syrengelas, D.
    Poulopoulos, P.
    Klimentopoulou, A.
    Mavridou, I.
    Michelakakis, H.
    CLINICAL THERAPEUTICS, 2007, 29 : S121 - S121
  • [39] Quantitative Systems Pharmacology-Based Digital Twins Approach Supplements Clinical Trial Data for Enzyme Replacement Therapies in Pompe Disease
    Kaddi, Chanchala
    Tao, Mengdi
    Bergeler, Silke
    George, Kelly
    Geerts, Hugo
    van der Graaf, Piet H.
    Batista, Julie L.
    Foster, Meredith
    Ortemann-Renon, Catherine
    Zaher, Atef
    Haack, Kristina An
    Zaph, Susana
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2025, 117 (02) : 579 - 588
  • [40] Immunophenotype associated with high sustained antibody titers against enzyme replacement therapy in infantile-onset Pompe disease
    Desai, Ankit K.
    Smith, P. Brian
    Yi, John S.
    Rosenberg, Amy S.
    Burt, Trevor D.
    Kishnani, Priya S.
    FRONTIERS IN IMMUNOLOGY, 2024, 14
12345